Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.34 per share.
- Transaction Volume: 20 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of shares by Mr. D S Redfern, Chief Strategy Officer, on July 15, 2016, via dividend reinvestment within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of an insider transaction.
Investor Verification Points
- Verify the total shareholding of Mr. D S Redfern following this acquisition to assess insider confidence.
- Confirm the dividend reinvestment policy details for the July 14, 2016 payment date.
- Note that this filing contains no operational or financial performance data; refer to the company's Form 20-F or interim reports for those metrics.